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Faecal calprotectin is considered to be a valid test for ruling out inflammatory bowel disease 
(IBD) in children with chronic gastrointestinal symptoms in specialist care. In contrast, 
faecal lactoferrin has higher specificity. The recent availability of both as point-of-care tests 
(POCTs) makes them attractive for use in primary care.
OBJECTIVE
To evaluate the test characteristics of calprotectin and lactoferrin POCTs for diagnosing 
IBD in symptomatic children.
METHODS
We defined two prospective cohorts of children with chronic gastrointestinal symptoms: 1) 
children presenting to primary care (primary care cohort); 2) children referred for specialist 
care (referred cohort). Baseline POCT results were compared with the outcome of either 
endoscopic assessment or 12 months follow-up. Clinicians were blinded to the POCT results. 
RESULTS
In the primary care cohort, none of the 114 children had IBD, and the calprotectin and 
lactoferrin POCTs had specificities of 0.95 (0.89–0.98) and 0.98 (0.93–0.99), respectively. In 
the referred cohort, 17 of the 90 children had IBD: the sensitivity of POCT calprotectin and 
POCT lactoferrin were both 0.94 (0.72-0.99); and the specificity was 0.93 (0.84-0.97) and 
0.99 (0.92-1.00), respectively. The POCT calprotectin could reduce the referral rate by 76% 
and POCT lactoferrin by 81%, while missing one child with IBD (6%). 
CONCLUSION
A diagnostic test strategy in primary care using a simple POCT calprotectin or lactoferrin 
has the potential to reduce the need for referral for further diagnostic work-up in specialist 
care, with a low risk of missing a child with IBD.
INTRODUCTION
In primary care, it can be difficult to differentiate between functional gastrointestinal 
disorders and organic disease, such as inflammatory bowel disease (IBD). Indeed, specialist 
care referral can ensure early diagnosis and treatment of children with IBD, and thereby 
reduce complications.1 Typically, referral is recommended for children with red flags, such 
as rectal bleeding, weight loss, or a family history of IBD.2 These red flags, however, are 
common and have little discriminative power.3,4 Therefore, simple, accurate tests are needed 
that can differentiate between functional and organic disorders in children with chronic 
gastrointestinal symptoms.
 Faecal calprotectin, a non-invasive test for intestinal inflammation, has a high rule-
out value among symptomatic children in specialist care (high sensitivity, reduced post-test 
probability of a normal test result).5-7 We have also shown a high rule-out value in children 
presenting in primary care.8 In both settings, faecal calprotectin was measured by enzyme-
linked immunosorbent assays (ELISA); however, point-of-care tests (POCT) have been 
developed with comparable accuracy to the ELISA.9 The concentration of calprotectin is 
stable at room temperature for 7 days, and only a few grams of stool are required. This enables 
the patient to deliver a stool sample at the general practice and receive a test result within 
15 minutes. Whereas faecal calprotectin, with its high sensitivity, is the most used faecal 
diagnostic test in children suspected for IBD, faecal lactoferrin has been shown to have a 
high specificity for IBD.10,11 Thus, lactoferrin might be of additional diagnostic value when 
used in combination with faecal calprotectin in point-of-care testing. 
 To date, the diagnostic accuracy of the calprotectin POCT, lactoferrin POCT and 
the combination of both, has not been examined for IBD among children with chronic 
gastrointestinal symptoms in primary care. Therefore, we studied the test characteristics in 
children presenting in primary care and children referred to specialist care.
METHODS
DESIGN AND PATIENTS
This was a prospective cohort study with a delayed-type cross-sectional design.12 Children 
were included in the Netherlands from July 2011 to July 2013 and were followed for 12 months. 
Parents of all children, and children aged ≥12 years, provided written informed consent, 
as appropriate. The study protocol was approved by the medical ethics committee of the 
University Medical Centre Groningen.
 We included two cohorts of children with chronic gastrointestinal symptoms. The 
primary care cohort included consecutive children recruited by 64 participating general 
practitioners (GPs) from 38 practices. The referred cohort included children selected from 
the primary care cohort who were referred for specialist care based on the presence of ≥1 red 
flags, and consecutive children referred by GPs and paediatricians who were included at one 
of four general hospitals and three academic centres. 
 The inclusion criteria were age 4–18 years, chronic diarrhoea (score 5, 6 or 7 on the 
Bristol Stool Form Scale13 for ≥2 weeks or ≥2 episodes in the past 6 months) and/or recurrent 
abdominal pain (≥2 episodes of abdominal pain or discomfort in the past 6 months). Exclusion 
criteria were known chronic organic gastrointestinal disease; endoscopic evaluation or faecal 
calprotectin testing in the preceding 6 months; chronic use of antibiotics, non-steroid 
anti-inflammatory drugs or oral corticosteroids in the previous 6 months; or difficulties in 
understanding questionnaires.
PATIENT FLOW
At baseline, the study GP or paediatrician assessed the presence of involuntary weight loss, 
rectal bleeding, family history of IBD, growth failure, extra-intestinal symptoms and peri-
anal lesions, based on a structured history and physical exam. In addition, a blood sample (for 
assessment of haemoglobin, C-reactive protein, erythrocyte sedimentation rate and platelet 
count) was taken (see red flags, Table 1). All children were clinically followed for 12 months. 
Children with ≥1 red flags (Table 1) at baseline or after 12 months’ follow-up were referred to a 
paediatric gastroenterologist who decided whether the child required endoscopic evaluation 
based on global assessment, physical examination, and blood test results. Children who did 
not had an indication for endoscopy received the reference standard of a clinical 12 months 
follow-up, because it was thought to be unethical to perform an invasive procedure under 
full anaesthesia in children with a low likelihood of IBD. The GPs or paediatricians of 
children lost to follow-up were contacted after 12 months in order to receive the most recent 
information required for making the final diagnosis.
POINT-OF-CARE TESTING
A stool sample tube, together with information on how to collect a stool sample, was provided 
at baseline. Stool was collected at home, shortly after inclusion, and sent to a laboratory for 
storage at -80°C until data collection was complete (September 2014). We used the dual 
calprotectin–lactoferrin POCT (CerTest Calprotectin–Lactoferrin combo, Zaragoza, 
Spain), which is a semi-quantitative immunochromatographic assay with a visual reading 
device. The test was performed at the laboratory of the Erasmus University Medical Centre 
in Rotterdam, according to the manufacturer’s instructions.
 The stick of the stool collection tube was dipped into different parts of the stool sample 
and added to the extraction buffer in the stool collection tube; or, for liquid samples, 15 μl 
was pipetted into the stool collection tube. The tube was shaken to ensure good sample 
distribution. Four drops from the sample in the stool collection tube were added to both 
windows of the POCT device (Window A for calprotectin and Window B for lactoferrin) 
and the results were read after 10 minutes. If a red-coloured line appeared in either window, 
the respective test was positive. The thresholds for positivity were >50 μg/g faeces and >10 μg/g 
faeces for the calprotectin and lactoferrin tests, respectively. The results were invalid when 
the green control line was absent. The testers were blinded to the clinical characteristics and 
diagnosis, and all clinicians and researchers were blinded to the outcomes of both POCTs.
DIAGNOSIS
IBD was diagnosed by esophagogastroduodenoscopy and ileocolonoscopy with histopathology 
of multiple biopsies, according to the revised Porto Criteria.14 Absence of IBD was defined 
as no endoscopic and histopathological evidence of IBD and/or no indication for endoscopy 
within or at 12 months’ follow-up. 
STATISTICAL ANALYSIS
A simple and non-invasive POCT might convince the GP to use this test in children with 
a low likelihood of IBD. In this population, false-positive results should be minimized to 
avoid unnecessary referrals for endoscopy. Therefore, we were mostly interested in a precise 
estimate of the specificity of both POCT results in the primary care cohort. A sample size 
calculation, which was based on a IBD prevalence rate of 5%, loss to follow-up of 10%, and 
specificity of 93%, generated a total of 118 children to determine the specificity with 95% 
confidence intervals (CIs) and adequate precision (i.e. 5%).12 In children in whom the GP 
considers a referral the likelihood of IBD increases. In this population, low false-negative 
rates are important to prevent delay in the diagnoses of children with IBD. Therefore, we 
were mostly interested in a precise estimate of sensitivity of both POCTs in the referred 
cohort. Based on a IBD prevalence rate of 20%, loss to follow-up of 10% and sensitivity of 
95%, we calculated a sample size of 100 children to determine sensitivity with 95% CIs and 
adequate precision (i.e. 10%).12 Moreover, we calculated specificity, positive predictive value 
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Red flags Measurement Positive 
Involuntary weight loss History Involuntary decrease in weight 
of > 1 kg
Rectal bleeding History Rectal bleeding with defecation 
without constipation according 
to ROME III criteria
Family history of IBD History Affected first-degree relative(s)
Growth failure History and physical examination Target height range > -1 
standard deviation score
Extra-intestinal symptoms Physical examination Eyes (episcleritis, scleritis, 
uveitis), skin (erythema nodo-
sum, pyoderma gangrenosum, 
psoriasis), mouth ulcers, finger 
clubbing, arthritis
Peri-anal lesions Physical examination Skin tag, haemorrhoid, fissure, 
fistula or abscess
Hemoglobin Local laboratory 4-12 years <7.1 mmol/l,
boys 12-18 years <8.1 mmol/l,
girls 12-18 years <7.4 mmol/l22
C-reactive protein Local laboratory >10 mg/l4
Erythrocyte sedimentation rate Local laboratory >20 mm/h4
Platelet count Local laboratory >450 x109/l23
Table 1. Definitions of red flags for inflammatory bowel disease.
IBD: inflammatory bowel disease
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(PPV), negative predictive value (NPV) with 95% CIs separately for each POCT in the 
referred cohort. In order to evaluate spectrum bias, subgroup analyses in children who were 
referred 1) by GP and 2) by general paediatrician were performed. To evaluate the accuracy of 
the structured clinical assessment in this study, we compared the proportion of children with 
red flags and the proportion of children with IBD in children with and without an endoscopy 
at baseline. Moreover, we evaluated the potential clinical impact of the different test results 
on referral rate or missed IBD diagnosis of the dual calprotectin-lactoferrin POCT with 
scenario analysis in the primary care cohort and referred cohort. We performed complete 
case analyses. Statistical analyses were performed with IBM SPSS for Windows, Version 
20.0 (IBM Corp., Armonk, NY, USA).
RESULTS
DESCRIPTIVE CHARACTERISTICS
The participant flow and baseline characteristics are summarized in Figure 1 and Table 2. 
We included 114 and 90 children in the primary care cohort and referred cohort, respectively. 
None of the primary care cohort and 17 (19%) of the referred cohort were diagnosed with 
IBD (Appendix 1). In the referred cohort, children referred by a general paediatrician more 
frequently had involuntary weight loss, rectal bleeding and extra-intestinal symptoms, and 
were more likely to be diagnosed with IBD, when compared with the children referred by a 
GP. Children who were subjected to an endoscopy at baseline had more frequently red flags 
(100%) and high risk for IBD (60%) than children who underwent no endoscopy at baseline 
(66% and 3%, respectively) (Table 2).
 The median intervals between faecal sampling and endoscopy were 4 and 8 days for 
children with and without IBD, respectively; however, 11 of the 27 children (2 missing 
samples) who underwent endoscopy had a delay >1 month. POCTs were not performed in 12 
children, and 9 test results (7.9%) were missing in the primary care cohort and 5 (5.6%) in the 
referred cohort. 
THE POCT CHARACTERISTICS
The characteristics of the calprotectin and lactoferrin POCTs for IBD, in children in primary 
care cohort and referred cohort are detailed in Table 3. In the primary care cohort, specificity 
of POCT calprotectin and POCT lactoferrin were 0.95 (0.89-0.98) and 0.98 (0.93-0.99), 
respectively. In the referred cohort, sensitivity of POCT calprotectin and POCT lactoferrin 
were both 0.94 (0.72-0.99); and the specificity was 0.93 (0.84-0.97) and 0.99 (0.92-1.00), 
respectively. In a subgroup analysis, the sensitivity of both POCTs in children referred to 
specialist care by their GP was 1.00 (0.57-1.00), the specificity for POCT calprotectin was 0.93 
(0.84-0.97) and for POCT lactoferrin 1.00 (0.94-1.00). The sensitivity and specificity of both 
POCTs in children referred to specialist care by their general paediatrician were 0.91 (0.62-0.93). 
SCENARIO ANALYSIS



























































































































































































































































































































































Test strategies N (%) Reduction of referrals Referrals
FCal - FLacto - 100 (95%) 21 (95%) -
FCal - FLacto + 0 - -
FCal + FLacto - 3 (3%) 1 (5%) 2 (2%)
FCal + FLacto + 2 (2%) - 2 (2%)
Referred cohort (n=85)
Referrals (n=85) IBD (n=16)
POCTs results indicates no referral
Test strategies N (%) Reduction of referrals Missed IBD cases 
FCal - FLacto - 65 (76%) 65 (76%) 1 (6%)
FCal + FLacto - 4 (5%) 4 (5%) 0
FCal - FLacto + 0 - -
POCTs results indicates referral
Test strategies N (%) Referrals IBD 
FCal + Flacto + 16 (19%) 16 (19%) 15 (94%)
FCal + FLacto - 4 (5%) 4 (5%) 0
FCal - Flacto + 0 - -
Table 4. Scenario analysis of the POCT combination results in both cohorts.
Abbreviations: FCal, faecal calprotectin; FLacto, faecal lactoferrin; POCT, point-of-care test; +, positive POCT; 
-, normal POCT
Notes: None of the children in primary care cohort were diagnosed with IBD. The test strategies are based on 
the assumption that children with both normal POCTs results should not be referred and both positive POCTs 
results should be referred. We showed both the impact on referrals and reduction of referrals for a combination 
of positive and normal result. Missing POCT: two children with red flags in primary care cohort; seven children 
without red flags in primary care cohort; five children in referred cohort; one child with IBD. 
Sens (95%CI) Spec (95% CI) PPV (95% CI) NPV (95% CI)
Primary care 
cohort (n=105)
FCal POCT - 0.95 (0.89-0.98) - -
FLacto POCT - 0.98 (0.93-0.99) - -
Referred 
cohort (n=85)
FCal POCT 0.94 (0.72-0.99) 0.93 (0.84-0.97) 0.75 (0.53-0.89) 0.98 (0.92-1.00)
FLacto POCT 0.94 (0.72-0.99) 0.99 (0.92-1.00) 0.94 (0.72-0.99) 0.99 (0.92-1.00)
Table 3. Test characteristics of the calprotectin and lactoferrin POCTs in primary care cohort and 
referred cohort.
Abbreviations: FCal: faecal calprotectin; FLacto: faecal lactoferrin; POCT, point-of-care test; PPV, positive 
































































































































































































































































































































































































































































































































































































































































































































































































































































142 | CHAPTER 7 EVALUATION OF POINT-OF-CARE TEST CALPROTECTIN AND LACTOFERRIN | 143 
7 7
144 | CHAPTER 7 EVALUATION OF POINT-OF-CARE TEST CALPROTECTIN AND LACTOFERRIN | 145 
7 7
both POCTs and in referred cohort 95%. In the primary care cohort, a normal POCT 
calprotectin and lactoferrin could hypothetically reduce 95% of referrals of children with red 
flags compared to referral of all children with red flags without missing a child with IBD. In 
the referred cohort, a normal POCT calprotectin and lactoferrin could hypothetically reduce 
referrals by 76%, compared to referral of all children considered for referral, but with the risk 
that 1 child (6%) with IBD would be missed (Table 4). 
DISCUSSION
SUMMARY
The POCTs showed high specificities in children presenting with chronic gastrointestinal 
symptoms in primary care, none of which were diagnosed with IBD. In children referred for 
further diagnostic work-up, both POCTs showed high sensitivities and negative predictive 
values. In both cohorts 95% or more of the children had the same outcome for both POCTs, 
which indicates that the tests provided little additional value to one another.
STRENGTHS AND LIMITATIONS
Evaluating test characteristics is a challenge when the prevalence of a disease is very low: a 
case-control design would overestimate test characteristics, while the preferred method of 
including consecutive at-risk children would be extremely time consuming and costly. In 
addition, using an invasive reference standard, risks exposing healthy children unnecessarily 
and would be ethically intolerable. Nevertheless, test characteristics urgently need to be 
evaluated in primary care.15 Based on this need, we used a pragmatic design that included 
consecutive children presenting with chronic gastrointestinal symptoms in primary care and 
selected high-risk children who were referred for specialist care.12 As expected, the prevalence 
and severity of IBD differed between these groups. In the referred cohort, children referred by 
a general paediatrician were more severely ill than children referred by their GP. This finding 
might reflect that, in the Netherlands, a paediatric gastroenterologist can see children if they 
are directly referred by a GP or indirectly referred by a paediatrician. Comparable healthcare 
systems exist in the United Kingdom, Scandinavia, Canada, New Zealand and Australia.16 
The sensitivity and specificity of both POCTs was slightly lower in the children who were 
referred by their general paediatrician than those who were referred by their GPs. Therefore, 
when interpreting our results, the effect of spectrum bias should be taken into account.
 As reference standards for diagnosis of IBD, we used endoscopy and 12 months’ follow-
up, because these are consistent with clinical experience. This may have introduced bias.17 
Nevertheless we feel the risk of misclassifying a child with IBD was extremely low with the 
introduction of follow-up, given that IBD is a chronic disease that often becomes clinically 
manifest within 12 months of presentation. Thus, children without red flags or a clinical 
indication for endoscopy over 12 months are very likely not to have IBD. In addition, IBD 
might have been missed at endoscopy, but persisting symptoms during follow-up may lead 
to further evaluation, therewith the risk of missing a child with IBD further decreases. 
Although the decision of the paediatric gastroenterologist was based on structured clinical 
information, the clinical judgement is to some degree subjective. The triage seemed efficient, 
because the children who were subjected to an endoscopy at baseline had more frequently red 
flags and higher risk for IBD than children who received no endoscopy at baseline. Although 
the use of two reference standards is not the ideal situation, following children for 12 months 
is the best option and represents reality of clinical care.18
 A GP or paediatrician would only have immediate access to a test result of calprotectine 
or lactoferrin if all children with abdominal symptoms bring along a sample of faeces. This is 
not feasible nor desirable. ‘Point-of-care’ therefore needs some explanation. In daily practice, 
the diagnostic strategy incorporates two consultations, one in which the test is ordered and 
a second in which the results are discussed. It is the latter consultation that will increase 
efficiency because the POCT can be conducted by a GP assistant, results will be available 
within 15 minutes and the patient can be seen immediately by a GP to discuss the results.
COMPARISON WITH EXISTING LITERATURE
We found no previous studies that have evaluated the characteristics of POCTs for 
discriminating IBD from other gastrointestinal disorders in children with chronic 
gastrointestinal symptoms. In one study, both tests were measured by ELISA and were 
significantly elevated in children with active IBD.19 The interaction between both tests was 
taken to indicate that the tests should be used together. We also expected that calprotectin 
and lactoferrin had added value to one another, not least because calprotectin showed high 
sensitivity and lactoferrin showed high specificity.5,10,11 Although lactoferrin had higher 
specificity than calprotectin, the improvement in diagnostic value of using a combination 
POCT was not substantial to both tests individually. 
 In a primary care study of adults with lower gastro-intestinal abdominal symptoms, 
researchers evaluated the diagnostic performance of both POCTs for identifying IBD.20 
Although they produced comparable specificities to our results, their sensitivities were lower. 
This might be explained by the adult study population and the use of different test assays and 
cut-off values.
IMPLICATIONS FOR RESEARCH AND PRACTICE 
No physician wants to miss a diagnosis of IBD in children presenting with chronic 
gastrointestinal symptoms; likewise, he or she must minimize referrals of children without 
IBD. In primary care, IBD has a low prevalence, so the probability of missing a child with 
IBD will be small and the probability of a referral of a child with functional gastrointestinal 
disorder will be high. To reduce the referral rate a test must have high specificity, which both 
POCTs (especially POCT lactoferrin) showed in the primary care cohort. The low false 
positive rates have the potential to reduce the number of referrals of children without IBD. 
The scenario-analysis showed that a normal POCT calprotectin or POCT lactoferrin test in 
children with red flags could reduce the number of referrals with 95% or 100%, respectively. 
None of the children without red flags was diagnosed with IBD during the 12 months follow-
up. Therefore, testing with both POCTs seems not of value in children without red flags. A 
disadvantage is that our sample was too small to include sufficient children with IBD in the 
primary care cohort. Therefore, we could not present positive and negative predictive values.
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 High sensitivities and negative predictive values are needed to minimize the rate of 
negative test results in children with IBD, which in turn, can delay further testing and 
treatment.21 The high sensitivities and negative predictive values of both POCTs in the 
referred cohort indicate that it can effectively rule out IBD in children in whom the GP 
considers referral. In addition, we showed that it could reduce the referral rate by 76% (POCT 
calprotectin) and 81% (POCT lactoferrin), while missing one child with IBD (6%). What is 
notable is that this study did not take into account referrals of other organic disease, such as 
celiac disease. Therefore, the presented numbers of referrals prevented, represent a ‘best case 
scenario’ and are applicable as far as IBD is concerned.
 A prospective cluster randomised controlled trial is needed to investigate the added value 
of both POCTs in primary care to effectively refer children for further diagnostic work-up 
for IBD. Moreover, studies are needed to examine the feasibility and cost-effectiveness of 
POCT in clinical practice. In our study, the POCTs were not performed at the GP’s office, 
but by experienced laboratory technicians. Therefore, interpretation by an inexperienced GP 
or medical assistant might be less reliable (e.g. the intensity of the test indicator line can 
vary). Also, we did not compare the cost and time efficiency of point-of-care testing with 
sample analyses in a laboratory for ELISA.
CONCLUSION
A diagnostic test strategy in primary care by using a simple POCT calprotectin or lactoferrin 
has the potential to reduce the need for referral for further diagnostic work-up in specialist 
care, with a very low risk of missing a child with IBD. Studies are required to investigate, 
the feasibility, whether POCTs actually will reduce referrals, and cost-effectiveness of the 
POCTs in children with chronic gastrointestinal symptoms in primary care.
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Appendix 1. The prevalence of positive calprotectin and lactoferrin POCTs by diagnosis
Abbreviations: FCal, faecal calprotectin; FLacto, faecal lactoferrin; POCT, point-of-care test; 
IBD, inflammatory bowel disease. 
agastroenteritis by salmonella enteric (primary care cohort n = 0; referred cohort n = 2), Shiga 
Toxin-Producing Escherichia Coli (STEC) (n = 1; n = 0), Giardia lamblia (n = 4; n = 1). 
Note: In one child the diagnosis was unknown, since the child refused endoscopic evaluation 
at baseline and an indicated 12 months follow-up evaluation by a GP because of presence of 
chronic gastrointestinal symptoms.
Diagnosis N (%) FCal POCT Flacto POCT
Primary care cohort
Functional gastrointestinal disorder 108 (95) 4/100 2/100
Gastroenteritisa 5 (45) 1 0
Refused endoscopy 1 (1) - -
Referred cohort
IBD
Crohn’s disease 7 (8) 6/6 6/6
Ulcerative colitis 8 (9) 7 7
IBD unclassified 2 (2) 2 2
Non-IBD
Functional gastrointestinal disorder 66 (73) 4/63 0/63
Gastroenteritisa 3 (3) 0 0
Reflux oesophagitis 1 (1) 0 0
Celiac disease 1 (1) 0 0
Solitary rectum ulcer 1 (1) 1 1
